The effects of hydralazine formulation and dose interval were assessed in 20 patients with hypertension well controlled on conventional hydralazine tablets, 100 mg twice daily, in addition to atenolol and a diuretic. The double-blind study used four regimens crossed over in random order at five-week intervals: placebo; conventional hydralazine 100 mg twice daily; conventional hydralazine 200 mg once daily; and slow-release hydralazine 200 mg once daily. Blood pressure and pulse rate were assessed soon after (2 5±0 9 h) and immediately before taking hydralazine (previous dose: once daily, 265±0-9 h; twice daily, 13 6±2 0 h). Seventeen patients completed the study. All hydralazine regimens were associated with significant falls in blood pressure. Once-daily treatment with conventional hydralazine was unsatisfactory, as its hypotensive effect waned at 24 h; there was a significant difference between the peak and trough effects on blood pressure and pulse in rapid acetylators. Compared with placebo twice-daily conventional hydralazine and oncedaily slow-release hydralazine gave satisfactory control for 24 hours in both rapid and slow acetylators, though the hypotensive effect was larger in the slow acetylators.
Introduction
Non-compliance is a common cause of apparent failure of antihypertensive drug treatment. '-4 The most important contributory factors are polypharmacy and frequent drug administration5 and for this reason simple once-daily regimens are recommended. Unfortunately, polypharmacy is often unavoidable since hypertension remains poorly controlled in at least one-fifth of patients taking beta-blocker plus diuretic combination. 6 Hydralazine is often added and has usually been prescribed twice daily since O'Malley et al7 found this to be as effective as a six-hourly regimen. It is not known whether oncedaily administration of hydralazine is equally effective. We describe a double-blind placebo controlled study comparing conventional hydralazine tablets given once daily, conventional hydralazine tablets given twice daily, and a slow-release preparation of hydralazine given once daily in patients with hypertension.
(121±02 mg/100 ml) and only one patient had renal impairment (serum urea 9-6 mmol/l (58 mg/100 ml), serum creatinine 145 ztmol/l (1-6 mg/100 ml)).
Patients with angina or recent myocardial infarction were excluded, and written informed consent was obtained before entry. The protocol was approved by the hospital ethics committee.
Methods
Drugs other than hydralazine were continued throughout the study. After a four-week run in period ordinary hydralazine was replaced by four treatments, each given for five weeks in a random crossover design with no intervals between treatments. The four treatments were: (a) placebo-four tablets morning, two tablets evening; (b) slow-release hydralazine-200 mg (four tablets) morning; two placebo tablets evening; (c) once-daily conventional hydralazine-200 mg (four tablets) morning; two placebo tablets evening; (d) twice-daily conventional hydralazine-100 mg (two tablets) + two placebo tablets morning; 100 mg (two tablets) evening. Hydralazine 50 mg tablets and placebos were identical, so that the study was double blind.
Clinical assessments were made at the same time of the morning in weeks two, four, and five of each treatment period. Blood pressure (phase V diastolic) was measured (mean of three values) after lying for five minutes and standing for one minute by the same observer using a Hawkesley random zero sphygmomanometer. The supine pulse rate was also measured. Patients were asked to list all new side effects, and all new events were recorded. Reasons for patient withdrawal were noted before the randomisation code was broken and those who withdrew were not replaced.
Compliance was assessed by counting tablets and patients were excluded if errors with any drug exceeded 150' on one occasion or 100'( on more than one occasion.
On weeks two and four patients had taken their morning dose of hydralazine before attending, thus the response was measured 2 5 ± 0-9 h (SD) after hydralazine. On week five the morning dose of hydralazine was omitted, thus the response was measured 13 6±2-0 h after the last dose in the case of twice-daily treatment, and 26-5 ±0 9 h after the last dose during once-daily treatments. The design therefore permitted an assessment of "peak" and "trough" effects of the drug.
Acetylator phenotype was assessed by the Bratton-Marshall method on urine six hours after taking oral sulphadimidine (10 mg/kg). 8 Statistics-Pulse and blood pressure measurements were compared using a paired or unpaired t test from the statistical package for the social sciences (University of Chicago). Data 
SIDE-EFFECTS
Dizziness was common on once-daily conventional treatment and usually occurred 1-3 hours after dosing; one patient reported the symptom at all of the three visits while receiving this preparation, three patients reported the symptoms on one visit. This effect was also reported by one patient on twice-daily and one on slow-release hydralazine. Two patients experienced a brief loss of consciousness during treatment with slow-release hydralazine but one of them had experienced blackouts before the trial. Both were seen about one hour after the blackout, when blood pressure and pulse rate were normal. Two patients complained of headache during treatment with twicedaily hydralazine, and one with slow-release hydralazine.
Discussion
O'Malley et al7 found the hypotensive effect of hydralazine to be similar whether the drug was given six-hourly or 12-hourly, but they emphasised the need for this to be confirmed as their study was limited to four black inpatients receiving hydralazine alone in a daily dose of 300 mg. Hydralazine is now rarely prescribed without a sympathetic blocking agent and the usual ceiling dose is 200 mg daily. It is surprising, therefore, that no study has hitherto attempted to extend these data. Our protocol enabled us to compare the changes in blood pressure and pulse rate within a dosage interval during active treatments and on placebo. During the twice-daily regimen the rise in blood pressure associated with omission of the morning dose was similar to that seen on placebo and we conclude that there is no need to administer hydralazine more than twice daily.
The possibility that hydralazine may be taken once daily without loss of blood-pressure control has not been explored formally, though it is known that hydralazine may bind to arterial walls for more than 48 hours. 9 Our findings suggest that once-daily administration of conventional hydralazine without prior knowledge of acetylator phenotype is unsatisfactory. Fluctuations in blood pressure and pulse rate within a dosage interval were significantly greater on this regimen than on placebo and side effects were rather common. Furthermore, the fall in standing blood pressure was not maintained throughout the dosing interval, though this appeared to be limited to rapid acetylators. In contrast, the twice-daily and once-daily slow hydralazine regimens were associated with significant reductions in blood pressure before and after dosing and fluctuations be-tween doses were similar to those seen on placebo. Thus hydralazine in a slow-release formulation may have a place in the management of patients with hypertension, particularly when non-compliance is a problem. Two patients reported blackouts with this formulation and more investigation is therefore required. It is reassuring, however, that a previous large open study has shown that the tolerability of once-daily slow hydralazine is similar to that of conventional twice-daily treatment.'0 Our data support the view that acetylator phenotype is a major determinant of response to hydralazinell-"3 though this has been disputed.'4 "I Generally the fall in blood pressure in slow acetylators was twice that seen in rapid acetylators. The difference in response between the phenotypes was most pronounced 24 hours after treatment with conventional hydralazine as a single morning dose. At this time the response of slow acetylators was similar to that observed on the other active treatments. In contrast, the trough effect during once-daily conventional hydralazine was negligible in rapid acetylators. These findings in part have a pharmacokinetic basis. The bioavailability and half life of hydralazine in the conventional preparation are greater in slow acetylators." 16 Administration of the slow-release formulation makes little difference to hydralazine elimination in slow acetylators but the apparent half life and bioavailability are both increased in rapid acetylators.'7 The duration of hypotensive effect is nevertheless much greater than that expected from plasma concentration data, presumably because of prolonged binding of hydralazine to arteriolar muscle wall.9
In conclusion, once-daily hydralazine in a slow-release form was as effective as conventional hydralazine given twice daily, and it may prove convenient to use provided that it is well tolerated. In slow acetylators the conventional once-daily and twice-daily regimens were equally effective. Once-daily treatment with conventional hydralazine was unsatisfactory in rapid acetylators.
We are grateful to Dr R W Elsdon-Dew of Ciba Laboratories for supplies of hydralazine tablets, and to Mrs M Dorey for dispensing them.
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REPORTS
Emergence of resistance after spectinomycin treatment for gonorrhoea due to f3-lactamaseproducing strain of Neisseria gonorrhoeae
The aminocyclitol antibiotic, spectinomycin, is commonly used for the treatment of gonorrhoea caused by ,B-lactamase-producing strains of Neisseria gonorrhoeae. Although spectinomycin-resistant penicillinsensitive gonococcal isolates have been found,' only one report of gonorrhoea caused by a spectinomycin-resistant ,3-lactamase-positive strain has been published. In that instance, the only isolate available for study was obtained after spectinomycin treatment had failed, presumably because treatment had produced chromosomal mutation leading to ribosomal changes and high-level resistance. 2 We report here the isolation of ,B-lactamase-producing strains of N gonorrhoeae from the same patient on five occasions during November 1981. Although the first two isolates were sensitive to spectinomycin, the remainder were resistant after treatment with spectinomycin.
Patient, methods, and results
A 27-year-old North African postgraduate student presented at the Praed Street Clinic, St Mary's Hospital, with a five-day history of urethral irritation and a two-dayhistoryof blood-stainedurethral dischargeon 2 November 1981.
He admitted to a casual sexual exposure in October in Canterbury, Kent. On examination he had unilateral tender inguinal lymphadenopathy and an obvious meatitis, from which oosed a persistent purulent discharge. Gonorrhoea was diagnosed on microscopy and culture of the urethral discharge. He was initially treated with 3-5 g ampicillin and 1-0 g probenecid orally. The strain of N gonorrhoeae, however, produced 3-lactamase.
On his next visit to the clinic four days later he still had a urethral discharge, from which a strain of spectinomycin-sensitive r-lactamaseproducing N gonorrhoeae was grown. He was given spectinomycin 2 g intramuscularly. Five days later, although his discharge had stopped, Gramnegative diplococci were seen on microscopy and he was given a further 4 g spectinomycin. The strain of Ngonorrhoeae isolated on this visit was, however, resistant to spectinormycin. Six days later he was free of symptoms. Since the previous isolate had been resistant to spectinomycin but was sensitive to tetracycline on disc testing, he was given a seven-day course of tetracycline 500 mg four times daily. A week later he was still free of symptoms but spectinomycin-resistant 3-lactamase-producing strains of Ngonorrhoeae were again isolated from his urethral exudate. He denied any further sexual contact since his first visit to the clinic. Because of the failure of treatment and the unusual resistance of the infecting strain, he was admitted to hospital on 1 December for further treatment and observation. His urethral discharge had recurred accompanied by dysuria. These symptoms resolved slowly when treated with cefuroxime (1-5 g with probenecid at once and 750 mg three times daily for three days). A week later he was finally discharged and has remained asymptomatic; follow-up cultures for Ngonorrhoeae have shown no growth.
All specimens of urethral exudate were cultured directly on to a selective medium consisting of GC agar base supplemented with 1 % IsoVitalex (Difco), vancomycin, colistin, trimethoprim, and nystatin3 and identified by Gram 
